BioSpace News Archive

The OVAL Phase 3 potential-registration study of VB-111 in ovarian cancer continues as planned towards the important interim analysis in 1Q 2020

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that it will report its fourth quarter and year-end 2019 financial results on Thursday, March 26, 2020.

The Global Partnership Against Coronavirus Alliance announced that through its Chairman Bruno Wu’s Seven Stars Medical group it is able to accelerate procurement and delivery of over 30 different types of supplies and equipment including PPE, and critical supplies of digital thermometers, N95 masks, gloves, facial protection, ventilators, testing kits and other critical medical supplies to assist U.S. hospitals in the battle to contain COVID-19.

Results Demonstrate AAV9 Gene Therapy of LAMP2B Reverses Clinical Manifestations of Danon Disease in Mouse Study

Applied DNA Sciences Inc. announced today the completion of design of a diagnostic kit for SARS-CoV-2 being developed for production via the Company’s proprietary PCR-based DNA manufacturing process.

The Canadian Society for Medical Laboratory Science is reassuring Canadians that the medical laboratory professionals who are performing a key role in the management of the current COVID-19 pandemic are amongst the best in the world.

Caregility, a clinical collaboration and communications company focused on providing secure, reliable two-way audio and video communications for any device and clinical workflow, in both inpatient and outpatient settings, announces the release of version 1.5 for its patented UHE platform.

GVOKE Pre-Filled Syringe (PFS) is available for home delivery through PillPack by Amazon Pharmacy

TRACON Pharmaceuticals announced today the appointment of Saundra Pelletier, Chief Executive Officer, President and Executive Director of Evofem Biosciences, Inc.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the company’s proprietary and patented Ii-Key immune system activation technology.